Vista Investment Management Acquires New Shares in Abbott Laboratories $ABT

by · The Markets Daily

Vista Investment Management bought a new position in Abbott Laboratories (NYSE:ABT – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 6,779 shares of the healthcare product maker’s stock, valued at approximately $615,000.

A number of other institutional investors have also recently made changes to their positions in ABT. Elevation Point Wealth Partners LLC bought a new stake in shares of Abbott Laboratories in the second quarter worth approximately $4,642,000. Daiichi Life Insurance Co. Ltd. purchased a new stake in Abbott Laboratories in the second quarter worth approximately $9,027,000. Foyston Gordon & Payne Inc bought a new stake in Abbott Laboratories in the 2nd quarter worth approximately $1,107,000. Commerce Bank purchased a new stake in Abbott Laboratories during the 2nd quarter valued at $40,622,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in shares of Abbott Laboratories during the 2nd quarter valued at $23,165,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

NYSE ABT opened at $110.48 on Tuesday. The business’s fifty day moving average is $103.06 and its 200 day moving average is $100.13. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The company has a market capitalization of $191.17 billion, a PE ratio of 35.75, a price-to-earnings-growth ratio of 2.18 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the prior year, the business posted $1.26 earnings per share. The business’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Analysts Set New Price Targets

ABT has been the subject of several research analyst reports. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a report on Thursday, August 13th. Citigroup raised their target price on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Piper Sandler restated an “overweight” rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. UBS Group reduced their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $119.50.

Check Out Our Latest Report on Abbott Laboratories

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Read More